Cidara is developing long-acting therapeutics designed to improve the standard of care for patients facing serious fungal or viral infections. The Company’s portfolio is comprised of new approaches aimed at transforming existing treatment and prevention paradigms, first with its lead Phase 3 antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) targeting influenza and other viral diseases from Cidara’s proprietary Cloudbreak® antiviral platform.
Burn Rate (Quarterly)
Click drug data to see upcoming trial info and prior data
Drug | Disease
Stage | Exp Date
See What The Community Is Saying - Click To See Full Post